Disclosures for "EMERGE Study: An Open-label Evaluation of the Efficacy and Safety of AXS-07 (MoSEICâ„¢ meloxicam-rizatriptan) for Migraine in Adults with Prior Inadequate Response to an Oral CGRP Inhibitor"